v3.26.1
Segment Reporting - Schedule of Segment Profit or Loss, Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Total revenue, net $ 75,388 $ 10,120
Less operating expenses:    
Cost of sales (96,369) (11,387)
Loss from operations (270,544) (241,426)
Other income, net 515 220
Foreign exchange gains (losses) 2,163 (989)
Interest income 18,980 32,355
Interest expense, net (36,670) (9,294)
Income tax expense (1,972) (1,528)
Net loss (287,528) (220,662)
Reportable Segment    
Segment Reporting Information [Line Items]    
Total revenue, net 75,388 10,120
Less operating expenses:    
Cost of sales (96,369) (11,387)
Research and clinical development (56,848) (37,831)
Product delivery (21,739) (78,428)
Commercial and Medical affairs (70,916) (55,219)
Support functions (80,899) (66,300)
Other segment expenses, net (19,161) (2,381)
Total operating expenses (345,932) (251,546)
Loss from operations (270,544) (241,426)
Other income, net 515 220
Foreign exchange gains (losses) 2,163 (989)
Interest income 18,980 32,355
Interest expense, net (36,670) (9,294)
Income tax expense (1,972) (1,528)
Net loss $ (287,528) $ (220,662)